Harrow (HROW) Competitors $39.04 +0.15 (+0.39%) Closing price 10/23/2025 04:00 PM EasternExtended Trading$38.92 -0.12 (-0.31%) As of 10/23/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. LEGN, MTSR, KRYS, PCVX, TGTX, PTCT, ARWR, ACLX, PTGX, and MENSShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Legend Biotech (LEGN), Metsera (MTSR), Krystal Biotech (KRYS), Vaxcyte (PCVX), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Protagonist Therapeutics (PTGX), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. Harrow vs. Its Competitors Legend Biotech Metsera Krystal Biotech Vaxcyte TG Therapeutics PTC Therapeutics Arrowhead Pharmaceuticals Arcellx Protagonist Therapeutics Jyong Biotech Legend Biotech (NASDAQ:LEGN) and Harrow (NASDAQ:HROW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations. Which has more volatility & risk, LEGN or HROW? Legend Biotech has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Do insiders and institutionals have more ownership in LEGN or HROW? 70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 15.2% of Harrow shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor LEGN or HROW? In the previous week, Legend Biotech had 7 more articles in the media than Harrow. MarketBeat recorded 9 mentions for Legend Biotech and 2 mentions for Harrow. Legend Biotech's average media sentiment score of 0.08 beat Harrow's score of 0.00 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer LEGN or HROW? Legend Biotech presently has a consensus price target of $66.56, suggesting a potential upside of 110.15%. Harrow has a consensus price target of $68.50, suggesting a potential upside of 75.46%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Legend Biotech is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73Harrow 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is LEGN or HROW more profitable? Harrow has a net margin of -4.49% compared to Legend Biotech's net margin of -40.83%. Harrow's return on equity of -2.18% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-40.83% -32.00% -20.07% Harrow -4.49%-2.18%-0.35% Which has stronger earnings & valuation, LEGN or HROW? Harrow has lower revenue, but higher earnings than Legend Biotech. Harrow is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$627.24M9.32-$177.03M-$0.88-35.99Harrow$199.61M7.24-$17.48M-$0.25-156.16 SummaryLegend Biotech and Harrow tied by winning 8 of the 16 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$2.64B$6.18B$10.59BDividend YieldN/A57.75%5.72%4.86%P/E Ratio-156.1623.9429.6728.46Price / Sales7.24778.82579.41225.02Price / Cash284.41165.1936.5560.64Price / Book20.025.5712.076.53Net Income-$17.48M$33.06M$3.32B$276.75M7 Day Performance-2.42%2.10%0.64%0.93%1 Month Performance-18.46%5.91%5.17%1.41%1 Year Performance-26.40%-2.82%61.77%31.59% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow2.3927 of 5 stars$39.04+0.4%$68.50+75.5%-28.0%$1.44B$199.61M-156.16180LEGNLegend Biotech2.911 of 5 stars$32.91+3.0%$66.56+102.2%-27.9%$5.90B$627.24M-37.402,609MTSRMetseraN/A$52.95-0.1%$55.75+5.3%N/A$5.57BN/A0.0081KRYSKrystal Biotech4.8285 of 5 stars$195.96+3.0%$223.00+13.8%+7.9%$5.51B$290.52M39.83210PCVXVaxcyte2.4185 of 5 stars$42.90+1.2%$106.25+147.7%-62.9%$5.50BN/A-10.44160Positive NewsTGTXTG Therapeutics4.3332 of 5 stars$35.12+1.3%$49.00+39.5%+44.8%$5.50B$329M94.92290News CoveragePositive NewsPTCTPTC Therapeutics3.2734 of 5 stars$68.36+3.7%$69.00+0.9%+57.3%$5.24B$806.78M9.811,410ARWRArrowhead Pharmaceuticals3.7922 of 5 stars$38.47+4.5%$43.14+12.1%+87.5%$5.09B$3.55M-30.05400Positive NewsACLXArcellx2.4802 of 5 stars$86.77-0.3%$113.08+30.3%-4.7%$4.82B$107.94M-25.3780PTGXProtagonist Therapeutics1.6135 of 5 stars$76.72-1.0%$74.00-3.5%+58.8%$4.82B$434.43M109.60120Positive NewsMENSJyong BiotechN/A$59.01+0.0%N/AN/A$4.49BN/A0.0031 Related Companies and Tools Related Companies Legend Biotech Alternatives Metsera Alternatives Krystal Biotech Alternatives Vaxcyte Alternatives TG Therapeutics Alternatives PTC Therapeutics Alternatives Arrowhead Pharmaceuticals Alternatives Arcellx Alternatives Protagonist Therapeutics Alternatives Jyong Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredBuffett’s Retirement PlayIn 2022, when Larry Benedict called the peak of the market, those who stayed in oil were slaughtered. Meanw...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HROW Stock Alerts